Novartis AG (ADR) (NYSE: NVS) is a Buy After Strong Q2

Novartis AG (ADR) (NYSE: NVS) was recently upgraded by Barclays to “equal weight” from “underweight” rating after the pharmaceutical company announced strong quarterly results. Novartis in the second quarter gained a huge amount by selling its stake in GSK consumer healthcare joint venture, as well as higher sales. The company also reiterated its fiscal 2018 outlook.

In the second quarter, Novartis net income increased to $7.77 billion from last year's $1.98 billion. Earnings per share increased to $3.34 from $0.84 last year.,/p>

Huge dividend Novartis

Investors in Novartis can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the Swiss market. Per share the analysts anticipate on a dividend of 2,95 CHF per share. Novartis 's dividend yield thus equals 3,61 percent. The average dividend yield of the pharmaceutical companies is a limited 0,5 percent.

Dividend returns Novartis

Over the current book year the total revenue will be 52,37 billion CHF (consensus estimates). This is slightly more than 2017's revenue of 50,14 billion CHF.

Historical revenues and results Novartis plus estimates 2018

fundamental research

The analysts expect for 2018 a net profit of 12,07 billion CHF. The majority of the analysts expects for this year a profit per share of 5,19 CHF. The price/earnings-ratio is then 15,75.

Recent target prices around 85 CHF

The most recent recommendations for the pharmaceutical company are from Berenberg, UBS and Barclays .

Novartis 's market capitalization is around 194,01 billion CHF.

At 16.55 the stock trades 0,78 percent higher at 81,72 CHF.

Historical stock prices Novartis

fundamental research novartis

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.